AZD 0120
Alternative Names: AZD-0120; BCMA-Antigen X Bispecific CAR-Modified T Cells-Gracell-Biotechnology; BCMA-Antigen X bispecific CAR-T cells; BCMA/CD19 dual-target CAR-T cell immunotherapy - Gracell Biotechnology; BCMA/CD19 dual-targeting CAR-T therapy; CD19-BCMA CAR-T cells; Dual CAR-BCMA-19; FasTCAR-T GC012F; GC 012; GC-012FLatest Information Update: 20 Jan 2025
Price :
$50 *
At a glance
- Originator Gracell Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Multiple myeloma; Systemic lupus erythematosus
- Phase 0 Myasthenia gravis
- No development reported Non-Hodgkin's lymphoma
Most Recent Events
- 06 Jan 2025 Gracell Biotechnologies plans a phase I trial for Myasthenia Gravis (Treatment-experienced) in China (IV) in February 2025 (NCT06759948)
- 25 Aug 2024 Phase-I/II clinical trials in Systemic lupus erythematosus (Treatment-experienced) in China (IV) (NCT06530849)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Second-line therapy or greater) in China